Randomised phase 3 trial: tegoprazan, a novel potassium‐competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis
Alimentary Pharmacology & Therapeutics2019Vol. 49(7), pp. 864–872
Citations Over TimeTop 10% of 2019 papers
Kwang Jae Lee, Byoung Kwan Son, Gwang Ha Kim, Hye‐Kyung Jung, Hwoon‐Yong Jung, Il‐Kwun Chung, In‐Kyung Sung, Jin Il Kim, Jong Hyeok Kim, Joon Seong Lee, Joong Goo Kwon, Jung Ho Park, Kyu Chan Huh, Kyung Sik Park, Moo In Park, Nayoung Kim, Oh Young Lee, Sam Ryong Jee, Sang Kil Lee, Sei Jin Youn, Sung Kook Kim, Soo Teik Lee, Su Jin Hong, Suck Chei Choi, Tae Nyeun Kim, Young Hoon Youn, Hyo Ju Park, Min Ja Kang, Chi Hye Park, Bong Tae Kim, Sangjun Youn, Geun Seog Song, Poong‐Lyul Rhee
Abstract
Once daily administration of tegoprazan 50 or 100 mg showed non-inferior efficacy in healing EE and tolerability to that of esomeprazole 40 mg.
Related Papers
- → Clinical pharmacology and safety profile of esomeprazole, the first enantiomerically pure proton pump inhibitor(2001)31 cited
- → Monitoring the growing use of esomeprazole(2019)3 cited
- รปแบบการใชยา Esomeprazole ชนดฉด ในโรงพยาบาลมหาสารคาม(2014)
- Comparative Study on Acid Suppression Effect of Esomeprazole and Other Proton Pump Inhibitors(2012)
- 위식도 역류 질환에 의한 비심인성 흉통 환자에서 에소메프라졸 20 mg 1일 2회 용법의 치료 효과 평가를 위한 공개, 무작위 배정 예비 연구(2020)